www.fdanews.com/articles/186707-fda-clears-novartis-combination-therapy-for-anaplastic-thyroid-cancer
![Red_Approved_Stamp.gif](https://www.fdanews.com/ext/resources/test/Drug-Images4/Red_Approved_Stamp.gif?t=1578447203&width=430)
FDA Clears Novartis Combination Therapy for Anaplastic Thyroid Cancer
May 8, 2018
The FDA approved Novartis’ combination therapy for anaplastic thyroid cancer that cannot be removed surgically.
The therapy uses a combination of the company’s Mekinist and Tafinlar. It is the first FDA-approved treatment for patients with such a form of cancer and the third for patients with this specific gene mutation.
The combination is also approved for use in a type of lung cancer with the BRAF V600E gene.